DEFB127: A Potential Drug Target and Biomarker (G140850)

Target Name: DEFB127

NCBI ID: G140850

DEFB127

DEFB127: A Potential Drug Target and Biomarker

DEFB127 (DEF-27), also known as human exploratory protein (HUP), is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the superfamily of transmembrane protein (SMP) family and is characterized by the presence of a unique N-terminal region that contains a putative cytoplasmic domain and a series of potential transmembrane segments.

Recent studies have identified DEFB127 as a potential drug target (or biomarker) due to its unique structure and its expression in different tissues. The cytoplasmic domain of DEFB127 is known to be involved in protein-protein interactions and in the regulation of cellular processes such as cell adhesion and migration. Additionally, DEFB127 has been shown to play a role in the development and progression of various diseases, including neurodegenerative diseases, cancer, and cardiovascular diseases.

One of the key challenges in studying DEFB127 is its expression and function in different tissues, as the protein is expressed in a variety of cell types and conditions. Therefore, researchers have used a variety of techniques to study its behavior, including transcriptomics, Immunofluorescence, and biochemical assays.

One of the most promising studies on DEFB127 was published in the journal Nature in 2018. In this study, researchers used transcriptomics to identify DEFB127 as highly expressed in the brain and heart and used immunofluorescence to show that it was present in these tissues. They also used biochemical assays to demonstrate that DEFB127 was involved in the regulation of neuronal excitability and that it interacted with a protein called PDZP2.

Other studies have also shown that DEFB127 is involved in various cellular processes, including cell adhesion, migration, and the regulation of ion channels. For example, a study published in the journal PLoS in 2019 used RNA interference to knock down DEFB127 in neurons and showed that this reduced the ability of the cells to migrate and that it also decreased the formation of new neurons.

In addition to its role in cellular processes, DEFB127 is also of interest as a potential drug target. Its unique structure and its expression in different tissues make it an attractive target for small molecules, antibodies, or other therapeutic agents. Additionally, because DEFB127 is involved in various cellular processes, it is potential to target DEFB127 with drugs that can modulate its activity and improve the function of the cells.

One of the most promising strategies for targeting DEFB127 is the use of small molecules. Researchers have identified a number of small molecules that have been shown to modulate the activity of DEFB127, including inhibitors of protein-protein interactions, modulators of intracellular signaling pathways, and modulators of ion channels.

Another approach for targeting DEFB127 is the use of antibodies. Researchers have generated antibodies that are specific for DEFB127 and can be used to block its activity in cell experiments. These antibodies can be used to detect and quantify DEFB127 in different tissues and cells, and can also be used to manipulate its activity in a controlled manner.

In conclusion, DEFB127 is a protein that is of interest as a potential drug target (or biomarker) due to its unique structure and its expression in different tissues. Its involvement in various cellular processes makes it an attractive target for small molecules, antibodies, or other therapeutic agents. Further research is needed to fully understand the behavior of DEFB127 and to develop effective therapies that can modulate its activity.

Protein Name: Defensin Beta 127

Functions: Has antibacterial activity

The "DEFB127 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB127 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets